SAFE, AFFORDABLE, AND EFFECTIVE MEDICINES FOR UKRAINIANS (SAFEMed) ACTIVITY
MONTHLY NEWS DIGEST NOVEMBER 2023
On October 17, the MOH approved legislation, drafted with support from SAFEMed partner Legal Alliance, requiring the international non-proprietary name (INN) of medicines to be indicated on paper and electronic prescriptions along with the mandatory indication of the form and dosage.This change is designed to expand use of generic medicines that are of equal quality but lower cost, thus increasing access and affordability of medicines for the Ukrainian population. Order No. 1806 amends the Rules for Prescribing Medicinal Products and Medical Devices, which has been in place since 2005, and states that, at the start of the new year, both paper and ePrescriptions will be issued under the trade name of the medicinal product only in the following cases:
These changes come after the Antimonopoly Committee of Ukraine recommended strengthening the requirements regarding the possibility for health care professionals to indicate the trade names of medicinal products in prescriptions, taking into account international experience. Also, according to the amendments, ePrescriptions for products providing reimbursed palliative care are issued by family doctors for all patients, except those with mental and behavioral disorders. For individuals with mental and behavioral disorders, ePrescriptions for these specified products are exclusively issued by doctors specializing in psychiatry, child psychiatry, and narcology.
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.
